Real-world use of macitentan reduces the risk of hospitalizations related to pulmonary arterial hypertension and improves health-related quality of life scores.
What is the safety, tolerability, and real-world effectiveness of macitentan in the management of pulmonary arterial hypertension?
This review highlights that real-world use of macitentan in pulmonary arterial hypertension confirms its safety profile and demonstrates benefits in reducing hospitalizations and improving quality of life.
Macitentan is a medication in the endothelin receptor antagonist class, approved for treatment of pulmonary arterial hypertension in 2013 based on the results of the pivotal SERAPHIN Trial (Study with an Endothelin Receptor Antagonist in Pulmonary arterial Hypertension to Improve cliNical outcome). Macitentan was shown in initial trials to reduce the likelihood of a morbidity/mortality event. Real-world use of this medication additionally reveals a reduced risk of hospitalizations related to pulmonary arterial hypertension, improved health-related quality of life scores, potential clinical utility in other conditions (such as chronic thromboembolic pulmonary hypertension and pulmonary hypertension related to congenital heart disease), and has a similar safety profile as demonstrated in initial trials.
Wong et al. (Sun,) conducted a review in pulmonary arterial hypertension. Macitentan was evaluated. Real-world use of macitentan reduces the risk of hospitalizations related to pulmonary arterial hypertension and improves health-related quality of life scores.